AI Engines For more Details: Perplexity Kagi Labs You
Nasal Congestion: Naphazoline hydrochloride acts as a nasal decongestant by constricting blood vessels in the nasal passages, which helps to relieve congestion and improve airflow. It is commonly used to alleviate symptoms of nasal congestion associated with allergies, sinusitis, and the common cold.
Allergic Rhinitis: Naphazoline hydrochloride can help relieve nasal congestion and other symptoms of allergic rhinitis, such as sneezing, itching, and runny nose, by reducing nasal inflammation and swelling.
Sinusitis: Naphazoline hydrochloride may be used as a short-term treatment for sinusitis to alleviate nasal congestion and facilitate drainage of the sinuses. It helps reduce swelling in the nasal passages, allowing mucus to drain more easily.
Common Cold: Naphazoline hydrochloride can provide temporary relief from nasal congestion caused by the common cold, helping individuals breathe more easily and feel more comfortable.
Eye Irritation: When used in eye drops, naphazoline hydrochloride helps relieve redness and irritation of the eyes caused by minor irritants such as dust, smoke, or pollen. It works by constricting blood vessels in the eyes, reducing redness and improving comfort.
Eye Allergies: Naphazoline hydrochloride eye drops may also be used to alleviate symptoms of eye allergies, including redness, itching, and watering eyes, by reducing ocular inflammation and irritation.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Acne | 0.3 | 0.3 | |
| ADHD | 0.5 | 0.3 | 0.67 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.5 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.3 | 0.5 | -0.67 |
| Allergy to milk products | 0.3 | 0.3 | 0 |
| Alzheimer's disease | 0.6 | 0.9 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0 | 0 | |
| Ankylosing spondylitis | 0.5 | 0.3 | 0.67 |
| Anorexia Nervosa | 0.8 | -0.8 | |
| Antiphospholipid syndrome (APS) | 0 | 0 | |
| Asthma | 0.9 | 0.8 | 0.13 |
| Atherosclerosis | 0.3 | 0.6 | -1 |
| Atrial fibrillation | 0.3 | 0.5 | -0.67 |
| Autism | 1.4 | 1 | 0.4 |
| Autoimmune Disease | 0.5 | -0.5 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Bipolar Disorder | 0.6 | 0.8 | -0.33 |
| Brain Trauma | 0.8 | -0.8 | |
| Carcinoma | 0.6 | 0.3 | 1 |
| Celiac Disease | 0.3 | 0.3 | 0 |
| Cerebral Palsy | 0.3 | 0.8 | -1.67 |
| Chronic Fatigue Syndrome | 0.6 | 0.3 | 1 |
| Chronic Kidney Disease | 0.6 | 0.5 | 0.2 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | -0.5 | |
| Chronic Urticaria (Hives) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.5 | -0.5 | |
| Cognitive Function | 0.8 | 0.5 | 0.6 |
| Colorectal Cancer | 0.8 | 0.8 | 0 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.8 | -0.8 | |
| COVID-19 | 0.6 | 1.3 | -1.17 |
| Crohn's Disease | 1.1 | 0.8 | 0.38 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.6 | 0.8 | -0.33 |
| Depression | 1.2 | 0.9 | 0.33 |
| Eczema | 0 | 0 | |
| Endometriosis | 0.3 | 0.5 | -0.67 |
| Epilepsy | 0.3 | 0.3 | 0 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 0.8 | 0.5 | 0.6 |
| Functional constipation / chronic idiopathic constipation | 0.3 | 1 | -2.33 |
| gallstone disease (gsd) | 0 | 0.5 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0 | 0 | |
| Generalized anxiety disorder | 0.6 | 0.8 | -0.33 |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 0.3 | 0.8 | -1.67 |
| Gulf War Syndrome | 0 | 0 | |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.8 | 0.3 | 1.67 |
| Heart Failure | 0.3 | 0.5 | -0.67 |
| Hidradenitis Suppurativa | 0.3 | 0.3 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.3 | 0.8 | -1.67 |
| Hypothyroidism | 0.3 | -0.3 | |
| Hypoxia | 0.3 | 0.2 | 0.5 |
| IgA nephropathy (IgAN) | 0.6 | 0.7 | -0.17 |
| Inflammatory Bowel Disease | 0.6 | 1 | -0.67 |
| Insomnia | 0.3 | 0.8 | -1.67 |
| Intelligence | 0.3 | 0.2 | 0.5 |
| Intracranial aneurysms | 0.3 | 0.3 | |
| Irritable Bowel Syndrome | 0.8 | 0.8 | 0 |
| ischemic stroke | 0.3 | 0.8 | -1.67 |
| Liver Cirrhosis | 1.1 | 0.8 | 0.38 |
| Long COVID | 0.6 | 0.8 | -0.33 |
| Low bone mineral density | 0.5 | -0.5 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.3 | 0.3 | 0 |
| Menopause | 0.5 | -0.5 | |
| Metabolic Syndrome | 1.1 | 0.8 | 0.38 |
| Mood Disorders | 1.2 | 1.1 | 0.09 |
| Multiple Sclerosis | 0.3 | 1 | -2.33 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.3 | 0.8 | -1.67 |
| Neuropathy (all types) | 0.3 | 0.5 | -0.67 |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1 | 0.8 | 0.25 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 1 | 1.1 | -0.1 |
| obsessive-compulsive disorder | 0.3 | 0.5 | -0.67 |
| Osteoarthritis | 0.3 | 0.3 | 0 |
| Osteoporosis | 1.1 | 0.3 | 2.67 |
| Parkinson's Disease | 1.1 | 1 | 0.1 |
| Polycystic ovary syndrome | 0.8 | 0.8 | 0 |
| Primary sclerosing cholangitis | 0.3 | 0.3 | |
| Psoriasis | 0 | 1 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.3 | 0.8 | 0.63 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 0.6 | 0.8 | -0.33 |
| Sjögren syndrome | 0.2 | 0.3 | -0.5 |
| Sleep Apnea | 1.1 | -1.1 | |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.8 | 0.9 | -0.13 |
| Systemic Lupus Erythematosus | 0.6 | 0.5 | 0.2 |
| Tic Disorder | 0.2 | -0.2 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.3 | 0.8 | -1.67 |
| Type 2 Diabetes | 1.1 | 0.8 | 0.38 |
| Ulcerative colitis | 0.3 | 1 | -2.33 |
| Unhealthy Ageing | 0.6 | 0.5 | 0.2 |
| Vitiligo | 0.3 | 0.3 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
